Richard D. Boyce, Ph.D.
Affiliations: | 2008 | University of Washington, Seattle, Seattle, WA |
Area:
Artificial Intelligence, Pharmacy, Computer ScienceGoogle:
"Richard Boyce"Parents
Sign in to add mentor| Ira Kalet | grad student | 2008 | University of Washington | |
| (An evidential knowledge representation for drug-mechanisms and its application to drug safety.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chapin MR, Kane-Gill SL, Li X, et al. (2024) Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System. Pharmacology Research & Perspectives. 13: e70047 |
| Chapin MR, Kane-Gill SL, Li X, et al. (2024) Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports. Pharmacology Research & Perspectives. 13: e70046 |
| Zhang T, Gephart SM, Subbian V, et al. (2023) Barriers to Adoption of Tailored Drug-Drug Interaction Clinical Decision Support. Applied Clinical Informatics. 14: 779-788 |
| Stottlemyer BA, McDermott MC, Minogue MR, et al. (2023) Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study. Therapeutic Advances in Drug Safety. 14: 20420986231181334 |
| Taneja SB, Callahan TJ, Paine MF, et al. (2023) Developing a Knowledge Graph for Pharmacokinetic Natural Product-Drug Interactions. Journal of Biomedical Informatics. 140: 104341 |
| Li X, Ndungu P, Taneja SB, et al. (2023) An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 through September 2021. Clinical and Translational Science |
| Kravchenko OV, Boyce RD, Gomez-Lumbreras A, et al. (2022) Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C). Bmj Open. 12: e066846 |
| Hansten PD, Tan MS, Horn JR, et al. (2022) Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management. Drug Safety. 1-20 |
| Malone DC, Villa-Zapata L, Gómez-Lumbreras A, et al. (2022) Authors' Response to Yoshihiro Noguchi's Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)". Drug Safety |
| Villa-Zapata L, Gómez-Lumbreras A, Horn J, et al. (2022) A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS). Drug Safety |